@article{4ee98b508913432badf475cda374e7b8,
title = "Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study",
abstract = "Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes and dialysis-dependent ESRD.",
author = "Thomas Idorn and Knop, {Filip K} and Morten J{\o}rgensen and Tonny Jensen and Marsela Resuli and Hansen, {Pernille M} and Karl Christensen and Holst, {Jens Juul} and Mads Hornum and Bo Feldt-Rasmussen",
year = "2013",
month = apr,
day = "26",
doi = "10.1136/bmjopen-2013-002764",
language = "English",
volume = "3",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group Ltd",
number = "4",
}